Difference between revisions of "Stanisław Burzyński"
(tp) |
|||
| Line 12: | Line 12: | ||
*[https://en.wikipedia.org/wiki/Antineoplaston Wikipedia on Antineoplaston] | *[https://en.wikipedia.org/wiki/Antineoplaston Wikipedia on Antineoplaston] | ||
*[https://en.wikipedia.org/wiki/Stanislaw_Burzynski Wikipedia on Stanislaw Burzynski] | *[https://en.wikipedia.org/wiki/Stanislaw_Burzynski Wikipedia on Stanislaw Burzynski] | ||
| + | |||
| + | ==References== | ||
| + | <references /> | ||
Revision as of 00:18, 28 June 2012
Stanislaw Rajmund Burzynski (born January 23, 1943 in Lublin, Poland) is a biochemist and a physician. He is the founder, president and chairman of Burzynski Research Institute Inc. , based in Houston and Stafford, Texas. Since December 1976, Burzynski administered peptides and their metabolites, which he calls antineoplastons, as a treatment against cancer.
Legal issues
In 1993, Burzynski was brought to court in Texas for treating patients with a therapy not approved by the Food and Drug Administration (FDA) and for selling antineoplastons in interstate commerce.[1][2] In 1998 the Texas Attorney General, Dan Morales, placed limits on his advertising of antineoplastons[3] and ordered him to cease and desist selling his products without FDA supervised clinical trials.[4] Burzynski appealed the limitations on his advertising on the grounds of free speech, but the appeal court upheld the decision, stating that "Burzynski's commercial speech does not concern a lawful activity."[1] Burzynski was also found guilty of fraud in 1994, as he claimed reimbursement from a health insurer for a cancer treatment administered illegally.[4] Burzynski will have a hearing with the Texas Medical Board in April 2012. The board might well revoke his approbation.
Main Article: Antineoplaston
Links
References
- ↑ 1.0 1.1 Texas State Board of Medical Examiners, Appellant v. Stanislaw R. Burzynski, M.D., Ph.D., Appellee Court judgement
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedopenjurist1987 - ↑ Template:Cite web
- ↑ 4.0 4.1 No. 93-2071 July 28, 1994. United States Court of Appeals, Fifth Circuit summary judgment.